|Articles|September 2, 2022
NeurologyLive® Friday 5 — September 2, 2022
Author(s)NeurologyLive® Staff
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 2, 2022.
Advertisement
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Cognition and Brain Health Biomarkers in Multiple Sclerosis
In episode 7 of the NeurologyLive® Ever Changing Face of MS series, "Cognition & Brain Health in Multiple Sclerosis," Randall Schapiro, MD, FAAN, and Jeffrey Wilken, PhD, explore the idea of cognition and brain health biomarkers in multiple sclerosis and provide imaging and diagnostic recommendations.
2: Overview of the Prevalence and Variety of Pediatric Sleep Disorders: Carol Rosen, MD
The professor of pediatrics at Case Western University provided insight on the typical sleep issues seen in children and adolescents, and how they impact overall quality of life.
3: NeuroVoices: Paul Lipkin, MD, on Improved CDC Guidelines for Developmental Milestones
In the latest edition of our in-depth Q&A series, the director of medical outpatient services at the Kennedy Krieger Institute discussed the changes and implications of new CDC guidelines on developmental milestones for growing children.
4: Institutional Perspectives in Neurology, Chaired by Augusto Miravalle, MD
Chaired by Augusto Miravalle, MD, of the University of Colorado, the presentations also feature Barry Hendin, MD, of the Center for Neurology and Spine; Ilana B. Katz Sand, MD, of Mount Sinai; Brett Fling, PhD, of Colorado State University; and Gavin Giovannoni, MBBCh, PhD, of Queen Mary University of London.
5: Role of the Cognitive Stress Test in Improving Future Alzheimer Clinical Trials: Rosie Curiel, PsyD
The associate professor of neuropsychology at the University of Miami Miller School of Medicine discussed how a new innovative tool can further characterize cognitive status and improve the evaluation of agents in development for Alzheimer disease.
—————————————————
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
NeurologyLive® Friday 5 — September 12, 2025September 12th 2025
Expanding the Alzheimer Drug Development PipelineSeptember 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
Expanding the Alzheimer Drug Development Pipeline
2
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
3
NeurologyLive® Friday 5 — September 12, 2025
4
FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency
5
